Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Cullinan Therapeutics Inc (NASDAQ: CGEM) was $10.14 for the day, down -2.22% from the previous closing price of $10.37. In other words, the price has decreased by -$2.22 from its previous closing price. On the day, 0.8 million shares were traded. CGEM stock price reached its highest trading level at $10.31 during the session, while it also had its lowest trading level at $9.985.
Ratios:
Our analysis of CGEM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.45 and its Current Ratio is at 10.45. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $30.UBS initiated its Buy rating on October 24, 2024, with a $30 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 23 ’25 when AHMED NADIM sold 9,922 shares for $10.01 per share. The transaction valued at 99,319 led to the insider holds 420,699 shares of the business.
Michaelson Jennifer sold 1,345 shares of CGEM for $13,463 on Dec 19 ’25. The Chief Scientific Officer now owns 132,635 shares after completing the transaction at $10.01 per share. On Dec 18 ’25, another insider, SUMER JACQUELYN L, who serves as the Chief Legal Officer of the company, sold 3,480 shares for $9.67 each. As a result, the insider received 33,652 and left with 135,432 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGEM now has a Market Capitalization of 599033280 and an Enterprise Value of 267625264.
Stock Price History:
The Beta on a monthly basis for CGEM is -0.10, which has changed by -0.14860427 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, CGEM has reached a high of $13.33, while it has fallen to a 52-week low of $5.68. The 50-Day Moving Average of the stock is 7.01%, while the 200-Day Moving Average is calculated to be 24.77%.
Shares Statistics:
CGEM traded an average of 1.30M shares per day over the past three months and 1172670 shares per day over the past ten days. A total of 59.08M shares are outstanding, with a floating share count of 39.32M. Insiders hold about 33.44% of the company’s shares, while institutions hold 77.36% stake in the company. Shares short for CGEM as of 1765756800 were 6821318 with a Short Ratio of 5.26, compared to 1763078400 on 6678836. Therefore, it implies a Short% of Shares Outstanding of 6821318 and a Short% of Float of 13.36.
Earnings Estimates
. The current market rating for Cullinan Therapeutics Inc (CGEM) reflects the collective analysis of 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.91, with high estimates of -$0.87 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$2.85 and -$4.14 for the fiscal current year, implying an average EPS of -$3.61. EPS for the following year is -$3.32, with 7.0 analysts recommending between -$2.14 and -$3.86.
